Cellectis Price/Sales
What is the Price/Sales of Cellectis?
The Price/Sales of Cellectis is 6.50
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on NASDAQ compared to Cellectis
What does Cellectis do?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Companies with price/sales similar to Cellectis
- Nyrada has Price/Sales of 6.49
- PTL Enterprises has Price/Sales of 6.49
- Dolby Laboratories has Price/Sales of 6.50
- Hercules Capital Inc has Price/Sales of 6.50
- Canopy Growth has Price/Sales of 6.50
- The Crypto has Price/Sales of 6.50
- Cellectis has Price/Sales of 6.50
- Hive Blockchain Technologies has Price/Sales of 6.50
- Marvell Tech. Grp Dl ,002 has Price/Sales of 6.51
- SWK has Price/Sales of 6.51
- Schroder European Real Estate Investment Trust Plc has Price/Sales of 6.51
- NextEra Inc has Price/Sales of 6.51
- First Trust New Opportunities MLP & Fund has Price/Sales of 6.51